Two Canadian provinces — Prince Edward Island, and Newfoundland and Labrador — are covering the cost of the oral formulation of Radicava (edaravone) for eligible residents with amyotrophic lateral sclerosis (ALS). Patients will have access through their provincial drug plans to Radicava Oral Suspension, developed along with…
Radicava Oral Suspension added to drug plans of 2 Canadian provinces
A particular genetic variant that boosts the activity of the NEAT1 gene can push the onset of amyotrophic lateral sclerosis (ALS) forward by more than three years, according to data from a large patient group in China. While the exact function of NEAT1 in ALS needs to be explored,…
When my late husband, Jeff, died of ALS in May 2020, I was awash in grief and lived in a world completely inhabited by memories. I obsessed over our every detail of our lives, large and small. Some thoughts were comforting and reminded me of our happy life together:…
A new advance in technology may pave the way for devices that could allow people with amyotrophic lateral sclerosis (ALS) who have lost the ability to speak to communicate using their thoughts alone. The new tech was described in a study, “High-resolution neural recordings improve the…
I must use the privilege of this column to acknowledge the passing of one of our ALS heroes, Ady Barkan. A young, stalwart, and dedicated husband and father, Ady spent the final few years of his life fighting for those without adequate healthcare in this country. Ady…
In the “Barbie” movie, Stereotypical Barbie, played by Margot Robbie, is living her best day, every day, in Barbie Land. When Ken has a mishap at the beach, he is whisked off to a mobile medical clinic and heals within seconds. Everyone attends Barbie’s blowout party. All the…
Having higher blood levels of uric acid may prevent or delay the decline in cognitive function in people with amyotrophic lateral sclerosis (ALS), according to a new study from Italy. High levels of uric acid are also associated with reduced odds of frontotemporal dementia, a form of dementia especially…
NeuroSense Therapeutics is planning to soon announce top-line safety and efficacy results from its PARADIGM trial, which is testing PrimeC in people with amyotrophic lateral sclerosis (ALS). News of trial findings being expected in December follows the dosing of a final patient in the randomized portion of…
The biotechnology company ProJenX recently received $15 million in funding to advance its experimental oral treatment prosetin for amyotrophic lateral sclerosis (ALS). This Series A financing round is essentially the next round of funding after seed money was used to rapidly develop the investigational treatment. Both rounds…
A person’s degree of exposure to multiple environmental pollutants — reflected by their presence in the blood — may be used to predict amyotrophic lateral sclerosis (ALS) risk and survival, according to new research. Greater exposure to these chemicals was associated with increased odds of an individual developing ALS,…
Recent Posts
- ALS nerve damage can occur without TDP-43 protein clumps: Study
- Dealing with loss, both big and small, in life with ALS
- Scientists use fat-based ‘bubbles’ to sneak ALS treatment into the brain
- Guest Voice: ALS hasn’t stopped this go-to guy from showing up as ‘Dad’
- HEALEY ALS platform trial launches new arm testing oral therapy NUZ-001